INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS .2. MRI ANALYSIS RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

D.W. Paty, D.K.B. Li, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group

Neurology April 1993;43:662–667

We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical results are presented in the preceding companion paper. Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans (median 80% reduction, $p = 0.0082$) and appearance of new lesions. In addition, there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups (mean group difference of 23%, $p = 0.001$). These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients.

Free Access to this article at www.neurology.org/content/43/4/662

Comment from Richard M. Ransohoff, MD, Associate Editor: Landmark demonstration that medication could change the natural history of MRI changes of MS and also introduced the concept that MRI could more sensitively detect MS progression than could clinical relapse-counting.

Neurology[®]

Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

D.W. Paty, D.K.B. Li and the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group

Neurology 2011;77:1431

DOI 10.1212/01.wnl.0000407006.93844.fb

This information is current as of October 10, 2011

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/77/15/1431.citation.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2011 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.